Skip to Main Content

Paper Details

GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.
Clin Pharmacol Drug Dev
7
2013
CA, CG100649, COX-2, Carbonic Anhydrase-I/II, Cyclooxygenase-2, GCG100649, acetazolamide, carbonic anhydrase (CA)-I/-II, cyclooxygenase (COX)-2, methazolamide, plasma
Author NameAffiliation
Garret A FitzGeraldInstitute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania
Garret A FitzGeraldUniversity of Pennsylvania Perelman School of Medicine
Garret A FitzGeraldInstitute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania
Garret A FitzGeraldUniversity of Pennsylvania Perelman School of Medicine
Carsten SkarkeInstitute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania
Carsten SkarkeUniversity of Pennsylvania Perelman School of Medicine
  • 1 - 6

Datasets

Release 1.2